[go: up one dir, main page]

WO2018161049A8 - Compositions et procédés pour induire des anticorps anti-vih-1 - Google Patents

Compositions et procédés pour induire des anticorps anti-vih-1 Download PDF

Info

Publication number
WO2018161049A8
WO2018161049A8 PCT/US2018/020788 US2018020788W WO2018161049A8 WO 2018161049 A8 WO2018161049 A8 WO 2018161049A8 US 2018020788 W US2018020788 W US 2018020788W WO 2018161049 A8 WO2018161049 A8 WO 2018161049A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
antibodies
compositions
inducing hiv
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/020788
Other languages
English (en)
Other versions
WO2018161049A1 (fr
Inventor
Barton F. Haynes
Kevin O. SAUNDERS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2017/020823 external-priority patent/WO2017152146A2/fr
Priority to US16/489,245 priority Critical patent/US11318197B2/en
Priority to CA3055204A priority patent/CA3055204A1/fr
Priority to EP18760878.1A priority patent/EP3589315A4/fr
Application filed by Duke University filed Critical Duke University
Publication of WO2018161049A1 publication Critical patent/WO2018161049A1/fr
Publication of WO2018161049A8 publication Critical patent/WO2018161049A8/fr
Priority to US16/977,408 priority patent/US20210009640A1/en
Priority to PCT/US2019/020436 priority patent/WO2019169356A1/fr
Priority to EP19761696.4A priority patent/EP3758734A4/fr
Priority to CA3092925A priority patent/CA3092925A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Selon certains aspects, l'invention concerne des immunogènes du VIH-1, comprenant des enveloppes (CH0848) et des sélections de ces dernières, et des procédés d'immunisation en essaim à l'aide de combinaisons d'enveloppes de VIH-1.
PCT/US2018/020788 2016-03-03 2018-03-02 Compositions et procédés pour induire des anticorps anti-vih-1 Ceased WO2018161049A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US16/489,245 US11318197B2 (en) 2016-03-03 2018-03-02 Compositions and methods for inducing HIV-1 antibodies
CA3055204A CA3055204A1 (fr) 2017-03-03 2018-03-02 Compositions et procedes pour induire des anticorps anti-vih-1
EP18760878.1A EP3589315A4 (fr) 2017-03-03 2018-03-02 Compositions et procédés pour induire des anticorps anti-vih-1
CA3092925A CA3092925A1 (fr) 2018-03-02 2019-03-01 Compositions comprenant des enveloppes de vih pour induire des anticorps anti-vih -1
EP19761696.4A EP3758734A4 (fr) 2018-03-02 2019-03-01 Compositions comprenant des enveloppes de vih pour induire des anticorps anti-vih -1
PCT/US2019/020436 WO2019169356A1 (fr) 2018-03-02 2019-03-01 Compositions comprenant des enveloppes de vih pour induire des anticorps anti-vih -1
US16/977,408 US20210009640A1 (en) 2018-03-02 2019-03-01 Compositions comprising hiv envelopes to induce hiv-1 antibodies

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
USPCT/US2017/020823 2017-03-03
PCT/US2017/020823 WO2017152146A2 (fr) 2016-03-03 2017-03-03 Compositions et procédés pour induire des anticorps du vih-1
US201862624620P 2018-01-31 2018-01-31
US62/624,620 2018-01-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/977,408 Continuation US20210009640A1 (en) 2018-03-02 2019-03-01 Compositions comprising hiv envelopes to induce hiv-1 antibodies

Publications (2)

Publication Number Publication Date
WO2018161049A1 WO2018161049A1 (fr) 2018-09-07
WO2018161049A8 true WO2018161049A8 (fr) 2018-10-04

Family

ID=63371208

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/020788 Ceased WO2018161049A1 (fr) 2016-03-03 2018-03-02 Compositions et procédés pour induire des anticorps anti-vih-1

Country Status (3)

Country Link
EP (1) EP3589315A4 (fr)
CA (1) CA3055204A1 (fr)
WO (1) WO2018161049A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10968255B2 (en) 2016-03-01 2021-04-06 Duke University Compositions comprising HIV envelopes to induce CH235 lineage antibodies
EP3423091A4 (fr) 2016-03-03 2019-10-30 Duke University Compositions et procédés pour induire des anticorps du vih-1
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
EP3519428A4 (fr) 2016-10-03 2020-07-08 Duke University Procédés d'identification d'immunogènes par ciblage de mutations improbables
US20210009640A1 (en) * 2018-03-02 2021-01-14 Duke University Compositions comprising hiv envelopes to induce hiv-1 antibodies
US12138304B2 (en) 2018-10-01 2024-11-12 Duke University HIV-1 envelope stabilizing mutations
EP3860637A4 (fr) * 2018-10-01 2022-08-17 Duke University Compositions comprenant des enveloppes de vih pour induire des anticorps contre le vih-1
CN113454100B (zh) * 2018-12-04 2024-08-23 洛克菲勒大学 Hiv疫苗免疫原
WO2022165182A1 (fr) * 2021-01-28 2022-08-04 Duke University Compositions comprenant des enveloppes de vih pour induire des anticorps contre le vih-1
US20240390482A1 (en) * 2021-03-08 2024-11-28 Duke University Hiv-1 envelope glycopeptide nanoparticles and their uses
US20250340597A1 (en) * 2021-10-11 2025-11-06 Duke University Compositions comprising hiv envelopes to induce hiv-1 antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014043386A1 (fr) * 2012-09-12 2014-03-20 Duke University Anticorps du lignage clonal
WO2015127108A1 (fr) 2014-02-19 2015-08-27 Duke University Enveloppes du vih -1 trimères des compositions et leurs utilisations
CA2944068A1 (fr) * 2014-03-31 2015-10-08 Duke University Compositions comprenant des enveloppes de ch848, et leurs utilisations
EP3189067B1 (fr) 2014-09-04 2021-05-19 The United States of America, as represented by The Secretary, Department of Health and Human Services Protéines de l'enveloppe du vih-1 et leur utilisation

Also Published As

Publication number Publication date
EP3589315A4 (fr) 2021-06-23
EP3589315A1 (fr) 2020-01-08
WO2018161049A1 (fr) 2018-09-07
CA3055204A1 (fr) 2018-09-07

Similar Documents

Publication Publication Date Title
WO2018161049A8 (fr) Compositions et procédés pour induire des anticorps anti-vih-1
WO2017152146A3 (fr) Compositions et procédés pour induire des anticorps du vih-1
WO2017151801A8 (fr) Compositions comprenant des enveloppes de vih pour induire des anticorps de lignée ch235
PH12020551716A1 (en) Anti-ror antibody constructs
MX2019007020A (es) Anticuerpos il-11.
WO2017173415A3 (fr) Compositions de conjugués saccharide-polypeptide polymérisables et leurs procédés d'utilisation
PH12019500365A1 (en) Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods
WO2016100985A3 (fr) Récepteurs antigéniques chimériques et leurs procédés d'utilisation
EP4364754A3 (fr) Anticorps anti-b7-h3 et conjugués anticorps-médicament
WO2017136820A3 (fr) Technologie fit-immunoglobuline et ses utilisations
EP4470557A3 (fr) Formulation d'anticorps anti-cgrp
WO2015168019A3 (fr) Conjugués médicament-anticorps anti-ptk7
WO2017214170A3 (fr) Anticorps baff-r et utilisations de ceux-ci
WO2015117008A3 (fr) Anticorps anti-vih de neutralisation large et épitope associé
MX2019006043A (es) Proteína de unión de antígeno prostático específico de membrana.
WO2016073789A3 (fr) Anticorps anti-fgfr2/3 et procédés d'utilisation de ceux-ci
MY191581A (en) Anti-pd-1 antibodies
WO2017214458A3 (fr) Anticorps anti-cd98 et conjugués anticorps-médicament
WO2016205531A3 (fr) Anticorps anti-her2 et leurs procédés d'utilisation
WO2017214462A3 (fr) Anticorps anti-cd98 et conjugués anticorps-médicament
IL266131A (en) Compositions for reprogramming cells into dendritic cells or antigen-presenting cells, methods and uses thereof
WO2015164392A8 (fr) Nouveaux anticorps antii-rnf43 et méthodes d'utilisation
EP4043031A3 (fr) Constructions à base d'antigènes du virus zika
MX2021005373A (es) Variantes de proteinas de union al factor h y metodos de uso de estas.
WO2017011340A3 (fr) Protéines et compositions immunisantes contenant des protéines de klebsiella et leurs procédés d'utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18760878

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3055204

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018760878

Country of ref document: EP

Effective date: 20191004